The NYT discusses the Food and Drug Administration's drug approval process which often allows drugs on the market before there is direct evidence of their effectiveness. It would have been worth noting how government patent monopolies distort this process.
Drug companies are anxious to gain patent rents and therefore will aggressively lobby the FDA to approve their drug, whether or not their has been sufficient testing. By contrast, in cases where there are already a number of drugs to treat a specific health condition, like those discussed in this article, it would be socially beneficial to require long and extensive testing, since there is little reason to believe that a new drug will offer substantial addition benefits.
The article quotes an industry representative as complaining that such a requirement would be expensive and discourage the development of new drugs. Of course that is precisely the desired outcome. We would rather see drug companies pursue cures for health conditions where current treatments are inadequate than try to develop copycat drugs. This point should have been discussed explicitly in the article.
There's too much at stake this November for us to quit. As we navigate another presidential election year, thoughtful independent journalism is more important than ever. We're committed to bringing you the latest news on what's really happening across the country this election season, shining a light on the stories corporate media overlooks and keeping the public informed about how power really works in America.
Quality reporting doesn't come for free, and we don't have corporate backers to rely on to fund our work. Everything we do is thanks to our incredible community of readers, who chip in a few dollars at a time to make what we do possible. This month, we're trying to raise $50,000 to help fuel our election coverage, and we've fallen behind on reaching our goal. Any amount you give today will bring us closer to making our reporting possible—and a generous donor has agreed to match all online donations, so your impact will be doubled.
